Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors

Cognitive impairment is a common non-motor symptom in Parkinson’s Disease (PD) and an important source of patient disability and caregiver burden. The timing, profile and rate of cognitive decline varies widely among individuals with PD and can range from normal cognition to mild cognitive impairmen...

Full description

Bibliographic Details
Main Authors: Paulina Gonzalez-Latapi, Ece Bayram, Irene Litvan, Connie Marras
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Behavioral Sciences
Subjects:
Online Access:https://www.mdpi.com/2076-328X/11/5/74
id doaj-ae6ce00cbc13415eb5544fe02a074d90
record_format Article
spelling doaj-ae6ce00cbc13415eb5544fe02a074d902021-05-31T23:54:05ZengMDPI AGBehavioral Sciences2076-328X2021-05-0111747410.3390/bs11050074Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk FactorsPaulina Gonzalez-Latapi0Ece Bayram1Irene Litvan2Connie Marras3Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, ON M5T2S8, CanadaParkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USAParkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USAEdmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, ON M5T2S8, CanadaCognitive impairment is a common non-motor symptom in Parkinson’s Disease (PD) and an important source of patient disability and caregiver burden. The timing, profile and rate of cognitive decline varies widely among individuals with PD and can range from normal cognition to mild cognitive impairment (PD-MCI) and dementia (PDD). Beta-amyloid and tau brain accumulation, oxidative stress and neuroinflammation are reported risk factors for cognitive impairment. Traumatic brain injury and pesticide and tobacco exposure have also been described. Genetic risk factors including genes such as <i>COMT, APOE</i>, <i>MAPT</i> and <i>BDNF</i> may also play a role. Less is known about protective factors, although the Mediterranean diet and exercise may fall in this category. Nonetheless, there is conflicting evidence for most of the factors that have been studied. The use of inconsistent criteria and lack of comprehensive assessment in many studies are important methodological issues. Timing of exposure also plays a crucial role, although identification of the correct time window has been historically difficult in PD. Our understanding of the mechanism behind these factors, as well as the interactions between gene and environment as determinants of disease phenotype and the identification of modifiable risk factors will be paramount, as this will allow for potential interventions even in established PD.https://www.mdpi.com/2076-328X/11/5/74Parkinson’s diseasedementiamild cognitive impairmentrisk factorsclinical profile
collection DOAJ
language English
format Article
sources DOAJ
author Paulina Gonzalez-Latapi
Ece Bayram
Irene Litvan
Connie Marras
spellingShingle Paulina Gonzalez-Latapi
Ece Bayram
Irene Litvan
Connie Marras
Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
Behavioral Sciences
Parkinson’s disease
dementia
mild cognitive impairment
risk factors
clinical profile
author_facet Paulina Gonzalez-Latapi
Ece Bayram
Irene Litvan
Connie Marras
author_sort Paulina Gonzalez-Latapi
title Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
title_short Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
title_full Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
title_fullStr Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
title_full_unstemmed Cognitive Impairment in Parkinson’s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors
title_sort cognitive impairment in parkinson’s disease: epidemiology, clinical profile, protective and risk factors
publisher MDPI AG
series Behavioral Sciences
issn 2076-328X
publishDate 2021-05-01
description Cognitive impairment is a common non-motor symptom in Parkinson’s Disease (PD) and an important source of patient disability and caregiver burden. The timing, profile and rate of cognitive decline varies widely among individuals with PD and can range from normal cognition to mild cognitive impairment (PD-MCI) and dementia (PDD). Beta-amyloid and tau brain accumulation, oxidative stress and neuroinflammation are reported risk factors for cognitive impairment. Traumatic brain injury and pesticide and tobacco exposure have also been described. Genetic risk factors including genes such as <i>COMT, APOE</i>, <i>MAPT</i> and <i>BDNF</i> may also play a role. Less is known about protective factors, although the Mediterranean diet and exercise may fall in this category. Nonetheless, there is conflicting evidence for most of the factors that have been studied. The use of inconsistent criteria and lack of comprehensive assessment in many studies are important methodological issues. Timing of exposure also plays a crucial role, although identification of the correct time window has been historically difficult in PD. Our understanding of the mechanism behind these factors, as well as the interactions between gene and environment as determinants of disease phenotype and the identification of modifiable risk factors will be paramount, as this will allow for potential interventions even in established PD.
topic Parkinson’s disease
dementia
mild cognitive impairment
risk factors
clinical profile
url https://www.mdpi.com/2076-328X/11/5/74
work_keys_str_mv AT paulinagonzalezlatapi cognitiveimpairmentinparkinsonsdiseaseepidemiologyclinicalprofileprotectiveandriskfactors
AT ecebayram cognitiveimpairmentinparkinsonsdiseaseepidemiologyclinicalprofileprotectiveandriskfactors
AT irenelitvan cognitiveimpairmentinparkinsonsdiseaseepidemiologyclinicalprofileprotectiveandriskfactors
AT conniemarras cognitiveimpairmentinparkinsonsdiseaseepidemiologyclinicalprofileprotectiveandriskfactors
_version_ 1721416253700046848